Monoclonal and Polyclonal Antibodies Against the HCV Envelope Proteins

Clinics in Liver Disease

Volumn 13, Issue 3, 2009, Pages 477-486

  Mir, Heshaam M ^a,b   Birerdinc, Aybike ^b   Younossi, Zobair M ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Antibodies; Hepatitis C; Monoclonal; Polyclonal; Treatment

Indexed keywords

BAVITUXIMAB; ENVELOPE PROTEIN; HEPATITIS C ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AB68; MONOCLONAL ANTIBODY AB6865; PEGINTERFERON; PLACEBO; RIBAVIRIN; RNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REVIEW; TREATMENT RESPONSE; VIRUS REPLICATION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOGLOBULINS; LIVER; VIRAL ENVELOPE PROTEINS;

EID: 67650528891     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.05.011     Document Type: Review

References (22)

1. Theodore S.M., and Jamal M. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 3 2 (2006) 41-46
2. Cholongitas E., and Papatheodoridis G.V. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 27 (2008) 866-884
3. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006) 705-714
4. Borgia G. Specific immunoglobulin against HCV: new perspectives. IDrugs 7 6 (2004) 570-574
5. Worman H.J. Current treatment of hepatitis C and its complications. The hepatitis C sourcebook (2002), McGraw-Hill, New York p. 14, 83-121
6. Farci P., Alter H.J., Wong D.C., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91 16 (1994) 7792-7796
7. Law M., Maruyama T., Lewis J., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14 1 (2008) 25-29
8. Galun E., Terrault N.A., Eren R., et al. Clinical evaluation (phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 46 (2007) 37-44
9. Lawitz E.J., Godofsky E.W., and Shan J.S. Multiple dose safety and pharmacokinetic study of bavituximab in patients with chronic hepatitis C virus (HCV) infection. 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Boston, MA. Nov 2-6, 2007. Available at:. http://www.natap.org/2007/AASLD/AASLD_74.htm Accessed February 7, 2009
10. Eren R., Landstein D., Terkieltaub D., et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80 6 (2006) 2654-2664
11. Stamataki Z., Grove J., Balfe P., et al. Hepatitis C virus entry and neutralization. Clin Liver Dis 12 (2008) 693-712
12. Pawlotsky J., Chaveliez S., and McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132 (2007) 1979-1998
13. Hsu M., Zhang J., Flint M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100 (2003) 7271-7276
14. Tscherne D.M., Jones C.T., Evans M.J., et al. Time and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80 (2006) 1734-1741
15. Blanchard E., Belouzard S., Goueslain L., et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80 (2006) 6964-6972
16. Reichert J.M. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 21 1 (2007) 1-7
17. Vanwolleghem T., Bukh J., Meuleman P., et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 47 6 (2008) 1846-1855
18. Schiano T.D., Charlton M., Younossi Z., et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 12 (2006) 1381-1389
19. Borgia G. HepeX-C XTL Biopharmaceuticals. IDrugs 5 8 (2004) 892-898
20. Bavituximab. Peregrine Pharmaceuticals Inc. Fall Winter 2008. Available at:. http://www.peregrineinc.com/images/stories/media/siteFiles/20081121_BavituximabAV.pdf Accessed February 7, 2009
21. Soares M.M., King S.W., and Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14 12 (2008) 1357-1362
22. Davis G.L., Nelson D.R., Terrault N., et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11 8 (2005) 941-949